THE ANALYSIS OF INFLUENCE OF CLINICAL PREDICTORS ON THE RESULTS OF TREATMENT WITH ERLOTINIB IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER (NSCLC)

被引：0
|
作者：
Salajka, Frantisek [1 ]
Pesek, Milos [2 ]
Krejci, Jana [3 ]
Skrickova, Jana [4 ]
Zatloukal, Petr
Koubkova, Leona
Grygarkova, Ivona
Hrnciarik, Michal [1 ]
Sticha, Michal [5 ]
机构：
[1] Univ Hosp, Dept Pneumol, Bulovka, Czech Republic
[2] Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[3] Charles Univ Hosp Plzen, Dept Pneumol, Plzen, Czech Republic
[4] Univ Hosp Brno, Dept Resp Dis & Tb, Brno, Czech Republic
[5] Masaryk Univ, CS-60177 Brno, Czech Republic
来源：
JOURNAL OF THORACIC ONCOLOGY | 2011年 / 6卷 / 06期
关键词：
NSCLC; erlotinib; clinical predictors;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S1293 / S1294
页数：2
相关论文
共 50 条
  • [41] Comorbidity in clinical trial patients with advanced or metastatic non-small cell lung cancer (NSCLC).
    Kosov, Maxim
    Kumar, Akhil
    Belotserkovskiy, Maxim
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Sunitinib in Combination With Erlotinib for the Treatment of Advanced/Metastatic Non-small Cell Lung Cancer (NSCLC): a Phase III Study
    Govindan, R.
    Krzakowski, M. J.
    Szczesna, A.
    Strausz, J.
    Makhson, A. N.
    Reck, M.
    Tye, L.
    Zhang, K.
    Chao, R. C.
    Scagliotti, G. V.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S557 - S557
  • [43] Treatment of advanced non-small cell lung cancer (NSCLC) in patients older than 70
    Richardet, M. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [44] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Schmid-Bindert, Gerald
    TARGETED ONCOLOGY, 2013, 8 (01) : 15 - 26
  • [45] Erlotinib for first line treatment in unselected patients (p) with advanced or metastatic non-small cell lung carcinoma (NSCLC)
    Jimenez, U.
    Gurpide, A.
    Isla, D.
    Garcia-Campelo, R.
    Firvida, J.
    Vinolas, N.
    Jaen, A.
    Montalar, J.
    Regueiro, P.
    Massuti, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Update on antiangiogenic treatment of advanced non-small cell lung cancer (NSCLC)
    Gerald Schmid-Bindert
    Targeted Oncology, 2013, 8 : 15 - 26
  • [47] EMT (Epithelial to Mesenchymal Transition) Markers and Response to Erlotinib in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
    Braun, E.
    Fidler, M. J.
    Shah, N.
    Kaiser, K. A.
    Basu, S.
    Harasty, H.
    Coon, J.
    Pool, M.
    Hensing, T.
    Bonomi, P. D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (12) : S533 - S533
  • [48] Erlotinib as single agent in patients with advanced or metastatic non-small cell lung cancer (NSCLC) and poor performance status
    Perez-Carrion, Ramon
    Dolores, Isla
    Garcia, Ramon
    Vinolas, Nuria
    Pallares, Cinta
    Gurpide, Alfonso
    Cobo, Manuel
    Juan, Luis Marti '
    Regueiro, Pilar
    Paz-Ares, Luis
    ANNALS OF ONCOLOGY, 2006, 17 : 236 - 236
  • [49] A multicenter phase II study of sorafenib in combination with erlotinib patients with advanced non-small cell lung cancer (NSCLC)
    Cho, B.
    Kim, S.
    Heo, D. S.
    Kang, S.
    Kim, H.
    Lee, D.
    Kim, D.
    Jung, M.
    Choi, J.
    Kim, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [50] Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC)
    Tsiara, Anna
    Liontos, Michalis
    Kaparelou, Maria
    Zakopoulou, Roubini
    Bamias, Aristotelis
    Dimopoulos, Meletios-Athanasios
    ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (08)
12345